Annovis Bio Inc ( (ANVS) ) has released its Q2 earnings. Here is a breakdown of the information Annovis Bio Inc presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Annovis Bio Inc., based in Malvern, Pennsylvania, is a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s.
In its second quarter of 2025, Annovis Bio reported significant progress in its clinical trials and financial performance. The company has been actively enrolling patients in its pivotal Phase 3 trial for early Alzheimer’s disease, with 76 clinical sites secured across the U.S. and over 400 patients screened. Additionally, Annovis has strengthened its intellectual property portfolio by transferring all patent families to crystal buntanetap.
The company’s financial results for the quarter showed an increase in cash and cash equivalents to $17.1 million, up from $10.6 million at the end of 2024. Annovis also reported a decrease in research and development expenses to $5.2 million and general and administrative expenses to $1.1 million compared to the same period last year. The net loss per common share improved to $0.32 from $0.44 in the previous year.
Looking ahead, Annovis Bio remains focused on completing its enrollment for the Alzheimer’s trial and advancing its Parkinson’s program. The management is optimistic about producing strong and reliable results as they continue to make strides in their research and development efforts.